Followers | 283 |
Posts | 1162 |
Boards Moderated | 0 |
Alias Born | 10/04/2020 |
Thursday, August 26, 2021 6:27:24 AM
I totally agree with everything you stated in particular your mention of a Bidding War for RGBP.
It's interesting you mentioned this for reason I just completed updating my recent post about the Top 5 Big Pharmas that might acquire RGBP and I mentioned a possible Bidding War and also I revised my estimated of the possible Buy Out Price, i.e. $5.75 to $6.25 per Share OR $21.7 Billion to $23.6 Billion.
My reason for this estimate range is Gilead bought Kite for nearly $12 Billion to acquire the only Patent they had at that time in 2017 which of course was an mRNA based for treating various cancers.
My thought is since Gilead was willing to shell out that kind of money over a single mRNA patent when at that time when little was know about it, today ALL Big Pharmas industry wide are well aware of the extraordinary value of this class of Patent based on the global success of the current mRNA Vaccine for Covid-19 that was recently FDA approved, and the Market Value of this class of Patent is absolutely enormous.
RGBP's Patent Portfolio of 24 Disruptive Biotechnology Patents that includes mRNA science would definitely have a perceived Market Value far beyond the $12 Billion Gilead paid Kite in 2017. $3.50 per share that I also considered would be low ball pricing that doesn't take into consideration all 24 of RGBP's Patents of which each have a Billion Dollar Market Capacity.
You are spot on however in the higher buy out estimate, only I believe now it will be higher!
Thanks again for the great post!
Here's the link for my revised post on the Top 5 Big Pharmas that may acquire RGBP:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165627226
I would appreciate your feedback after you review my revised post.
Thank you-
Be well and prosper...
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM